AGIO

Agios Pharmaceuticals, Inc. Press Releases

$40.37
*  
1.16
 negative 
2.96%
Get AGIO Alerts
*Delayed - data as of Apr. 17, 2014 14:52 ET 
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    AGIO Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Agios Initiates Phase 1 Study of AG-348, a First-in-class PKR Activator, for Pyruvate Kinase Deficiency
4/17/2014 8:00:00 AM - Business Wire

Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma
4/8/2014 1:15:00 PM - PR Newswire

Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers
4/6/2014 10:30:00 AM - Business Wire

Agios Announces Clinical and Preclinical Data to be Presented at AACR Annual Meeting 2014
3/31/2014 8:00:00 AM - Business Wire

Candidate Selection for Clinical Trials, Financial Results, and Patient Enrollments for Phase I Study - Analyst Notes on Synta, Ziopharm, Aastrom, Agios, and OncoMed
3/25/2014 8:00:00 AM - PR Newswire

Agios Enrolls First Patient in Phase 1 Study of AG-120 in Advanced Solid Tumors with an IDH1 Mutation
3/24/2014 8:00:00 AM - Business Wire

Agios Announces Enrollment of First Patient in Phase 1 Study of AG-120 in Advanced Hematologic Malignancies with an IDH1 Mutation
3/19/2014 8:00:00 AM - Business Wire

Flagship Ventures Partner David Berry Named a 2014 Young Global Leader by the World Economic Forum
3/11/2014 11:00:00 AM - PR Newswire

Marketing Authorization Applications, Quarterly Dividends, Publication of Clinical Trial Data, Acquisitions, and Financial Results - Analyst Notes on Regeneron, Amgen, Sangamo, Alnylam, and Agios
3/11/2014 9:08:00 AM - PR Newswire

Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
3/6/2014 7:30:00 AM - Business Wire

Agios Pharmaceuticals to Webcast Conference Call Discussing Fourth Quarter and Full Year 2013 Financial Results on March 6, 2014
2/27/2014 5:24:00 PM - Business Wire

Agios Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference
2/24/2014 8:00:00 AM - Business Wire

Pronutria® Announces Launch of Two Clinical Trials
2/13/2014 8:30:00 AM - PR Newswire

Agios Pharmaceuticals to Present at the 2014 Leerink Swann Global Healthcare Conference
2/6/2014 8:00:00 AM - Business Wire

Agios Pharmaceuticals Exercises Option to U.S. Development and Commercialization Rights for IDH1 Program under Celgene Collaboration
2/3/2014 8:00:00 AM - Business Wire